Australia markets close in 1 hour 1 minute

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
4.2800-0.0150 (-0.35%)
At close: 5:29PM CEST
Full screen
Previous close4.2950
Open4.4000
Bid4.3200 x 0
Ask4.3850 x 0
Day's range4.2800 - 4.4300
52-week range4.1050 - 12.2400
Volume311,090
Avg. volume378,103
Market cap853.436M
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-1.2000
Earnings date25 Aug 2021 - 30 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.70
  • Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
    GlobeNewswire

    Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study

    Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study -- Independent Data Safety and Monitoring Board (DSMB) issues positive opinion on safety for ilixadencel in combination with Keytruda® -- Immunicum AB (publ) today announced that the independent Data Safety and Monitoring Board (DSMB) for the Phase Ib/II ILIAD study completed its assessment of the Phase Ib part of the ILIAD trial, evaluating the Company’s off-the-shelf,

  • Change in Number of Shares and Votes in Immunicum AB (publ)
    GlobeNewswire

    Change in Number of Shares and Votes in Immunicum AB (publ)

    Press Release 30 June 2021 Change in Number of Shares and Votes in Immunicum AB (publ) The number of shares and votes in Immunicum AB (publ) has changed during June as a result of 33,233,433 new shares being issued in the directed issue carried out by the company on 17 June 2021. The directed issue has resulted in an increase in the number of shares in Immunicum by 33,233,433 shares, from 166,167,166 shares to 199,400,599 shares and an increase in the share capital by SEK 1,661,671.65, from SEK

  • Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001
    GlobeNewswire

    Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001

    Press Release 28 June 2021 Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001 Immunicum AB (publ) today announced that it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the Company’s lead cancer relapse vaccine candidate, DCP-001. DCP-001 is derived from Immunicum’s proprietary human DCOne cell line and is currently being evaluated as a cancer relapse va